|
|
||||||||
Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, MD 20892.
The number of deaths due to cancer in the United States reached an all-time high of 453,450 deaths in 1984 and, due to the dynamics of population growth, will continue to increase if the risk of dying from cancer does not change. Between 1970 and 1984, the total Person-Years of Life Lost (PYLL), the sum of the difference between the actual age at death and the expected remaining lifetime for each person who died of cancer, increased for most cancer sites as well as for all sites combined. In 1984, 6,881,281 person-years of life were lost due to cancer deaths, up from 5,303,668 in 1970. The exceptions are those cancers for which there has been major progress in either prevention or treatment; e.g., stomach and cervix uteri (prevention) and testicular, Hodgkin's disease, leukemia, and childhood cancers (treatment). The Average Years of Life Lost (AYLL) per person dying from cancer in 1984 was generally less than in 1970. Overall, each person who died from cancer in 1984 died 15.2 years earlier than his/her life expectancy. The greatest loss was for those who died of childhood cancers (66.9 years earlier), followed by testicular cancer (35.8 years earlier). The least loss relative to the expectation of life was for those who died of prostate cancer. The 25,400 men who died from prostate cancer in 1984 died an average of nine years earlier than otherwise expected.
This article has been cited by other articles:
![]() |
T.-M. Pham, Y. Fujino, R. Ide, N. Tokui, T. Kubo, T. Mizoue, I. Ogimoto, S. Matsuda, and T. Yoshimura Years of life lost due to cancer in a cohort study in Japan Eur J Public Health, April 1, 2009; 19(2): 189 - 192. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Y. Bilimoria, C. M. Balch, D. J. Bentrem, M. S. Talamonti, C. Y. Ko, J. R. Lange, D. P. Winchester, and J. D. Wayne Complete Lymph Node Dissection for Sentinel Node-Positive Melanoma: Assessment of Practice Patterns in the United States Ann. Surg. Oncol., June 1, 2008; 15(6): 1566 - 1576. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Wientjes, J. H. Zheng, L. Hu, Y. Gan, and J. L-S. Au Intraprostatic Chemotherapy: Distribution and Transport Mechanisms Clin. Cancer Res., June 1, 2005; 11(11): 4204 - 4211. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kakehi Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era Jpn. J. Clin. Oncol., January 1, 2003; 33(1): 1 - 5. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Salazar, W. B. Carter, J. L. B. Johnson, and K. Olson Evaluation of Breast Self-Examination Beliefs Using a Decision Model West J Nurs Res, August 1, 1993; 15(4): 403 - 421. [PDF] |
||||
![]() |
K. E. Richert-Boe and L. L. Humphrey Screening for Cancers of the Lung and Colon Arch Intern Med, December 1, 1992; 152(12): 2398 - 2404. [Abstract] [PDF] |
||||
![]() |
K. E. Richert-Boe and L. L. Humphrey Screening for Cancers of the Cervix and Breast Arch Intern Med, December 1, 1992; 152(12): 2405 - 2411. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |